A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes

Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models

(2010) Odelia Katz et al.   JOURNAL OF ENDOCRINOLOGY

Erythropoietin Over-Expression Protects against Diet-Induced Obesity in Mice through Increased Fat Oxidation in Muscles

(2009) Pernille Hojman et al.   PLoS One

The non-haematopoietic biological effects of erythropoietin

(2008) Murat O. Arcasoy   BRITISH JOURNAL OF HAEMATOLOGY

Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice

(2008) Yasuhiro Izumiya et al.   Cell Metabolism

Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle

(2008) Carsten Lundby et al.   JOURNAL OF APPLIED PHYSIOLOGY

CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice

(2008) P.J. Bugelski et al.   JOURNAL OF BIOTECHNOLOGY

Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice

(2007) Robert E. Schmidt et al.   EXPERIMENTAL NEUROLOGY